Alto Neuroscience, a biotech company focused on developing personalized treatments for mental health conditions, has successfully priced its initial public offering (IPO) at $129 million. The offering was upsized, with shares priced at $16 each, the high end of the proposed range. This milestone was celebrated with a listing on the New York Stock Exchange (NYSE) under the ticker symbol $ANRO. Numinus Wellness, which is associated with the ticker symbol $NUMI, sold off its shares in Alto Neuroscience ahead of the IPO. The company's mission to redefine psychiatry by leveraging individual neurobiology for personalized treatment has been highlighted as part of its market debut.
"Redefining Psychiatry." Join us in celebrating @AltoNeuro's work to match patients with the right medication more efficiently. $ANRO https://t.co/31UbJDjJzH
.@AmitEtkin, MD, PhD, Founder + CEO of @AltoNeuro, talks about their unique approach to personalized psychiatric treatment and how they're addressing critical unmet needs in mental health care on #NYSEFloorTalk with @JudyKShaw. #IPO #biotech #mentalhealth https://t.co/xUq3DRCClA
Brain drug developer Alto Neuroscience prices $129M IPO https://t.co/riTWSM7K6k $ANRO by @gwendolynawu
.@AltoNeuro is on a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. Join us in celebrating its listing on NYSE today! $ANRO https://t.co/bHKqZhv7SJ
Alto Neuroscience is on a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. Join us in celebrating its listing on NYSE today! $ANRO https://t.co/ztf6EbBUfQ
.@AltoNeuro is on a mission. To bring every person suffering from a mental health condition the right treatment for them, right away. Join us in celebrating its listing on NYSE today! $ANRO https://t.co/vVpEI7uSXS
CNS disorder biotech Alto Neuroscience prices upsized IPO at $16, the high end of the range $ANRO $IPO #IPO https://t.co/C42AxC2fW8
Brain drug developer Alto Neuroscience prices $129M #IPO https://t.co/3DKvxx8G8p by @gwendolynawu $ANRO #biotech
Numinus Wellness Sells Off Shares In Alto Neuroscience Ahead Of IPO $NUMI #Alto #biotech #IPO https://t.co/PPivrTs2g8 via @TheDeepDive_ca
Alto Neuroscience is looking to raise roughly $101 million from an IPO. https://t.co/KwWFe2wIc7
CNS disorder biotech Alto Neuroscience sets terms for $101 million IPO $ANRO $IPO #IPO https://t.co/t7laMDumEW